0001213900-21-010260.txt : 20210218 0001213900-21-010260.hdr.sgml : 20210218 20210218115656 ACCESSION NUMBER: 0001213900-21-010260 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 EFFECTIVENESS DATE: 20210218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Saliogen Therapeutics, Inc. CENTRAL INDEX KEY: 0001845309 IRS NUMBER: 844170116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-389813 FILM NUMBER: 21648492 BUSINESS ADDRESS: STREET 1: 1500 DISTRICT AVENUE CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (650) 906-9468 MAIL ADDRESS: STREET 1: 1500 DISTRICT AVENUE CITY: BURLINGTON STATE: MA ZIP: 01803 D 1 primary_doc.xml X0708 D LIVE 0001845309 Saliogen Therapeutics, Inc. 1500 DISTRICT AVENUE BURLINGTON MA MASSACHUSETTS 01803 (650) 906-9468 DELAWARE None None Corporation true 2020 Raymond Tabibiazar 1500 District Avenue Burlington MA MASSACHUSETTS 01803 Executive Officer Director Joseph Higgins 1500 District Avenue Burlington MA MASSACHUSETTS 01803 Executive Officer Director Sukumar Nagendran 1500 District Avenue Burlington MA MASSACHUSETTS 01803 Director While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. Sean Stalfort 1500 District Avenue Burlington MA MASSACHUSETTS 01803 Director Biotechnology Decline to Disclose 06b false 2021-02-04 false true false 0 BTIG, LLC 122225 None None 600 MONTGOMERY STREET 6TH FLOOR SAN FRANCISCO, CA CALIFORNIA 94111 CA CALIFORNIA IL ILLINOIS NJ NEW JERSEY VA VIRGINIA false 20000000 20000000 0 false 3 0 0 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Saliogen Therapeutics, Inc. /s/ Rayomond Tabibiazar Raymond Tabibiazar Chief Executive Officer 2021-02-18